About Eukaryotic translation initiation factor 2 subunit 2
Eukaryotic translation initiation factor 2 subunit 2 (EIF2S2) is a protein
from Homo sapiens identified by UniProt accession
P20042, 333 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 2 subunit 2 |
|---|
| UniProt accession | P20042 |
|---|
| Gene | EIF2S2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 333 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (87)
Diseases linked to this target (Open Targets).
- freckles · score 0.16
- sunburn · score 0.15
- glomerular filtration rate · score 0.15
- body mass index · score 0.12
- skin sensitivity to sun · score 0.12
- type 2 diabetes mellitus · score 0.11
- platelet count · score 0.09
- lean body mass · score 0.09
- hepatocellular carcinoma · score 0.08
- leukocyte count · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P20042-F1 | alphafold | PREDICTED | 64.94 | — |
Amino-acid sequence (333 residues)
MSGDEMIFDP TMSKKKKKKK KPFMLDEEGD TQTEETQPSE TKEVEPEPTE DKDLEADEED TRKKDASDDL DDLNFFNQKK KKKKTKKIFD IDEAEEGVKD LKIESDVQEP TEPEDDLDIM LGNKKKKKKN VKFPDEDEIL EKDEALEDED NKKDDGISFS NQTGPAWAGS ERDYTYEELL NRVFNIMREK NPDMVAGEKR KFVMKPPQVV RVGTKKTSFV NFTDICKLLH RQPKHLLAFL LAELGTSGSI DGNNQLVIKG RFQQKQIENV LRRYIKEYVT CHTCRSPDTI LQKDTRLYFL QCETCHSRCS VASIKTGFQA VTGKRAQLRA KAN
Explore Eukaryotic translation initiation factor 2 subunit 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets